- Home
- FFIE vs XGN Comparison
FFIE vs XGN Comparison
Compare FFIE & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIE
- XGN
- Stock Information
- Founded
- FFIE 2014
- XGN 2002
- Country
- FFIE United States
- XGN United States
- Employees
- FFIE N/A
- XGN N/A
- Industry
- FFIE Auto Manufacturing
- XGN Medical Specialities
- Sector
- FFIE Consumer Discretionary
- XGN Health Care
- Exchange
- FFIE Nasdaq
- XGN Nasdaq
- Market Cap
- FFIE 97.5M
- XGN 86.6M
- IPO Year
- FFIE N/A
- XGN 2019
- Fundamental
- Price
- FFIE $1.60
- XGN $3.58
- Analyst Decision
- FFIE
- XGN Strong Buy
- Analyst Count
- FFIE 0
- XGN 2
- Target Price
- FFIE N/A
- XGN $7.50
- AVG Volume (30 Days)
- FFIE 11.5M
- XGN 154.7K
- Earning Date
- FFIE 11-06-2024
- XGN 03-17-2025
- Dividend Yield
- FFIE N/A
- XGN N/A
- EPS Growth
- FFIE N/A
- XGN N/A
- EPS
- FFIE N/A
- XGN N/A
- Revenue
- FFIE $537,000.00
- XGN $55,751,000.00
- Revenue This Year
- FFIE $10,958.67
- XGN $7.13
- Revenue Next Year
- FFIE $617.65
- XGN $19.14
- P/E Ratio
- FFIE N/A
- XGN N/A
- Revenue Growth
- FFIE N/A
- XGN 8.00
- 52 Week Low
- FFIE $0.99
- XGN $1.30
- 52 Week High
- FFIE $156.00
- XGN $6.22
- Technical
- Relative Strength Index (RSI)
- FFIE 51.72
- XGN 38.58
- Support Level
- FFIE $1.49
- XGN $3.63
- Resistance Level
- FFIE $1.86
- XGN $4.55
- Average True Range (ATR)
- FFIE 0.18
- XGN 0.50
- MACD
- FFIE 0.04
- XGN -0.13
- Stochastic Oscillator
- FFIE 46.84
- XGN 2.75
About FFIE Faraday Future Intelligent Electric Inc.
Faraday Future Intelligent Electric Inc is a global shared intelligent mobility ecosystem. It is poised to break the boundaries between the Internet, IT, creative, and auto industries with product and service offerings that integrate new energy, AI, Internet, and sharing models.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.